Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DiaSorin SpA Announces FDA Approval of Aldosterone Assay on CLIA; FDA Approval of TSH and fT4


Wednesday, 17 Apr 2013 03:21am EDT 

DiaSorin SpA announced that the Food and Drug Administration (FDA) has approved the Aldosterone assay on CLIA technology. The Company has thus introduced in the United States market the Aldosterone assay on the LIAISON Platforms, expanding in the United States with additional products. Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex. Its function is to increase sodium reabsorption in the kidneys. The test is primarily used for the diagnosis of hypertension. DiaSorin SpA also announced that it has also received the FDA approval for two other products, TSH and fT4, which enrich the current offer of the Endocrinology family on the LIAISON analyzers, thus implementing the expansion of the Company's menu in the United States market. Currently, there are 30 assays available on the LIAISON platforms in the United States. 

Related Company News

Company Quote

35.3
 --
27 Jan 2015